JP2014129324A5 - - Google Patents

Download PDF

Info

Publication number
JP2014129324A5
JP2014129324A5 JP2013113125A JP2013113125A JP2014129324A5 JP 2014129324 A5 JP2014129324 A5 JP 2014129324A5 JP 2013113125 A JP2013113125 A JP 2013113125A JP 2013113125 A JP2013113125 A JP 2013113125A JP 2014129324 A5 JP2014129324 A5 JP 2014129324A5
Authority
JP
Japan
Prior art keywords
composition
liver
maltitol
oral
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013113125A
Other languages
Japanese (ja)
Other versions
JP6437183B2 (en
JP2014129324A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2013113125A priority Critical patent/JP6437183B2/en
Priority claimed from JP2013113125A external-priority patent/JP6437183B2/en
Publication of JP2014129324A publication Critical patent/JP2014129324A/en
Publication of JP2014129324A5 publication Critical patent/JP2014129324A5/ja
Application granted granted Critical
Publication of JP6437183B2 publication Critical patent/JP6437183B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (14)

マルチトールを有効成分として含有する、肝機能改善用組成物。 A composition for improving liver function, comprising maltitol as an active ingredient. マルチトールを有効成分として含有し、血中ＡＳＴ値及びＡＬＴ値の改善作用を特徴とする、肝機能改善用組成物。 A composition for improving liver function, comprising maltitol as an active ingredient and characterized by improving blood AST value and ALT value. マルチトールを有効成分として含有する、肝機能障害の予防および／または治療のための組成物。 A composition for preventing and / or treating liver dysfunction, comprising maltitol as an active ingredient. アルコール性脂肪肝、非アルコール性脂肪肝、アルコール性脂肪肝炎、非アルコール性脂肪肝炎、肝硬変および肝がんからなる群より選択される肝疾患の予防および／または治療のための、請求項３に記載の組成物。 Claim 3 for the prevention and / or treatment of liver disease selected from the group consisting of alcoholic fatty liver, nonalcoholic fatty liver, alcoholic steatohepatitis, nonalcoholic steatohepatitis, cirrhosis and liver cancer. The composition as described. 脂肪含有量が１０重量％以上である食事の食前、食中、食後および食間のいずれかに投与されるものである、請求項３または４に記載の組成物。 The composition according to claim 3 or 4, which is administered before, during, after or between meals having a fat content of 10% by weight or more. 錠剤、カプセル剤、顆粒剤、散剤、経口液剤、シロップ剤、経口ゼリー剤、口腔用錠剤、口腔用スプレー剤、口腔用半固形剤および含嗽剤からなる群より選ばれる剤形のものである、請求項１〜５いずれかに記載の組成物。 It is of a dosage form selected from the group consisting of tablets, capsules, granules, powders, oral solutions, syrups, oral jelly, oral tablets, oral sprays, oral semisolids and mouthwashes. The composition according to any one of claims 1 to 5. インスリン抵抗性改善薬、抗酸化剤、脂質異常症治療薬、肝庇護薬およびアンジオテンシンII１型受容体拮抗薬からなる群より選ばれる１種以上の薬剤をさらに含む、請求項１〜６いずれかに記載の組成物。 Insulin sensitizers, antioxidants, lipid lowering agents, liver supporting agents and further comprise one or more agents selected from the group consisting of angiotensin II1 type receptor antagonists, to any claim 1 to 6 The composition as described. 組成物が機能性飲食品である、請求項１〜５のいずれかに記載の組成物。The composition in any one of Claims 1-5 whose composition is functional food-drinks. 組成物がサプリメントである、請求項１〜６のいずれかに記載の組成物。The composition according to claim 1, wherein the composition is a supplement. 組成物が医薬組成物である、請求項３〜７のいずれかに記載の組成物。The composition according to any one of claims 3 to 7, wherein the composition is a pharmaceutical composition. 動物肝臓、サメの肝油、豚肝臓の酵素分解ペプチド、ポリコサノール、葛花、Ｌ−オルニチン、ノブドウ、レスベラトロール、クルミ、クルミポリフェノール、α−リポ酸、アーティチョーク、アスタキサンチン、アスパラギン酸、アラニン、イエロードック、ウコン、牡蠣、ガジュツ、ガラナ、甘草、キョウオウ、クロレラ、グリチルリチン、高麗人参、コーヒー、ゴマリグナン、S-アデノシルメチオニン、シジミ、システイン、シリマリン、スピルリナ、チャンカピエドラ、田七人参、フェヌグリーク、セサミン、タウリン、ダンデライオン、フコイダン、マリアアザミ、ラクトフェリン、ラフィノース、霊芝、レシチンおよびローヤルゼリーからなる群より選ばれる１種以上の天然物または天然由来物質をさらに含む、請求項１〜１０いずれかに記載の組成物。 Animal liver, shark liver oil, porcine liver enzyme-degrading peptide, policosanol, kuzuhana, L-ornithine, grapevine, resveratrol, walnut, walnut polyphenol, α-lipoic acid, artichoke, astaxanthin, aspartic acid, alanine, yellow dock , Turmeric, oysters, gadgets, guarana, licorice, leopard, chlorella, glycyrrhizin, ginseng, coffee, sesame lignan, S-adenosylmethionine, shijimi, cysteine, silymarin, spirulina, champapiedra, ginseng, fenugreek, sesamin, taurine , Dandelion, further comprising fucoidan, milk thistle, lactoferrin, raffinose, Reishi, one or more natural or naturally derived material selected from the group consisting of lecithin and royal jelly, claims 1 to 10, The composition according to any misalignment. 非ヒト動物における肝機能障害の予防および／または治療のための、マルチトールを有効成分として含有する非ヒト動物用医薬組成物。   A pharmaceutical composition for non-human animals containing maltitol as an active ingredient for the prevention and / or treatment of liver dysfunction in non-human animals. マルチトールを非ヒト動物に投与することを含む、非ヒト動物における肝機能障害を予防および／または治療する方法。 A method for preventing and / or treating liver dysfunction in a non-human animal, comprising administering maltitol to the non-human animal. マルチトールを飲食品に配合または添加することを特徴とする、機能性飲食品の製造方法。 The manufacturing method of functional food / beverage products characterized by mix | blending or adding maltitol to food / beverage products.
JP2013113125A 2012-11-30 2013-05-29 Liver function improving agent Active JP6437183B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013113125A JP6437183B2 (en) 2012-11-30 2013-05-29 Liver function improving agent

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012263134 2012-11-30
JP2012263134 2012-11-30
JP2013113125A JP6437183B2 (en) 2012-11-30 2013-05-29 Liver function improving agent

Publications (3)

Publication Number Publication Date
JP2014129324A JP2014129324A (en) 2014-07-10
JP2014129324A5 true JP2014129324A5 (en) 2016-07-21
JP6437183B2 JP6437183B2 (en) 2018-12-12

Family

ID=51408084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013113125A Active JP6437183B2 (en) 2012-11-30 2013-05-29 Liver function improving agent

Country Status (1)

Country Link
JP (1) JP6437183B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020209429A1 (en) * 2019-04-12 2020-10-15 주식회사 비엔지삶 Ginseng candy comprising bioactive components of palmyra palm and artichoke, and method of preparing same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0399018A (en) * 1989-09-11 1991-04-24 Otsuka Pharmaceut Co Ltd Agent for promoting secretion of glucagon-like peptide hormone
JPH0753375A (en) * 1993-08-10 1995-02-28 Tooa Eiyoo Kk Therapeutic agent for hepatopathy
KR101356330B1 (en) * 2004-12-24 2014-01-27 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 Hepatic function remedial agent
CN101410101A (en) * 2006-03-31 2009-04-15 明治乳业株式会社 Anti-fat-accumulation composition
JP5041780B2 (en) * 2006-10-23 2012-10-03 エムジーファーマ株式会社 Liver disorder improving composition
JP5465834B2 (en) * 2008-01-15 2014-04-09 雪印メグミルク株式会社 Liver function protectant
JP5876205B2 (en) * 2009-02-06 2016-03-02 松谷化学工業株式会社 Method for improving deficiency of sweetness of D-sorbose in sweetener comprising D-sorbose and improving sweetness persistence
JP6157928B2 (en) * 2012-05-29 2017-07-05 上野製薬株式会社 Fat accumulation inhibitor in the liver

Similar Documents

Publication Publication Date Title
Torres-Fuentes et al. A natural solution for obesity: Bioactives for the prevention and treatment of weight gain. A review
ES2788166T3 (en) Compositions and methods using a polyphenol for musculoskeletal health
JP2014129323A5 (en)
CN105935364B (en) Composition comprising ginsenoside F2 for preventing or treating non-alcoholic liver disease
JP5752359B2 (en) Weight gain inhibiting composition and food containing the same
EP2992933B1 (en) Ginsenoside f2 for prophylaxis and treatment of liver disease
JP6157928B2 (en) Fat accumulation inhibitor in the liver
KR101559130B1 (en) Composition comprising herbal extract for preventing or treating obesity
Memudu et al. Retention of testicular integrity and testosterone levels upon ingestion of garlic cloves (Allium sativum) in the Sprague-Dawley rat
JP6161438B2 (en) Fat accumulation inhibitor and / or fat accumulation reducing agent
JP2014129324A5 (en)
JP6660668B2 (en) UCP-1 expression promoter
JP5969529B2 (en) Anti-inflammatory agent
WO2016068267A1 (en) Agent for improving sickness behavior symptoms
EP3616705A2 (en) Composition for improving prevention and treatment of fatty liver containingamomum vilosum
JP6553375B2 (en) UCP-1 expression promoter
KR20160058810A (en) Liver function and/or pancreatic function improving agent
KR101591460B1 (en) Composition comprising mixture extract of Ephedra sinica, Rheum palmatum L and Arnebia euchroma for preventing or treating obesity
KR101729236B1 (en) TLR7 agonist agent for treatment and prevention of liver disease
JP6692638B2 (en) PPARδ activator
JP2015003877A (en) Composition comprising hydroxytyrosol or salt thereof
JP2015160841A (en) Hepatopathy inhibitor induced by ethanol
JP6437183B2 (en) Liver function improving agent
KR101644755B1 (en) Composition for preventing or treating stroke or degenerative brain disease
Lee et al. Effects of an aqueous extract of purple sweet potato on nonalcoholic fatty liver in high fat/cholesterol-fed mice